Biocure Enters into Exclusive Joint R&D Agreement with Pharos Vaccine Inc. for Overseas Market of CAR T-Cell Products
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (formerly Gravis Energy Corp.) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has entered into an agreement with Pharos Vaccine Inc. for the development of overseas market of CAR T-cell products on exclusive basis. The two Companies will work together in developing anti-CD19 CAR T-cell therapy products, conduct...
2019-05-16 8:40 AM EDT
Biocure Announces the Appointment of a New Director
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that effective of today's date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.After completing a PhD in Biochemistry at Texas A&M university and an MBA at Rice University, Danny Joh moved to the San Francisco area to build a career in the biopharma industry. For twenty years, he has expanded his...
2019-03-14 9:00 AM EDT
BiocurePharm, Korea ("BPK") Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 96,404 shares at $11.45 CAD per share for gross proceeds of $1,103,749. After the issuance of new BPK shares,...
2019-02-28 4:30 PM EST
Biocure Technology Corp Announces a MOU with the Government of Uzbekistan and Gold-Dream LLC to Build a Manufacturing Plant to Produce Biosimilars
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a Memorandum of Understanding with the Agency of Development of the Pharmaceutical Industry under the Ministry of Health, The Republic of Uzbekistan (herein after called "MHU") and Gold-Dream LLC (herein after called "GDL") on Feb 15th, 2019...
2019-02-19 9:00 AM EST
Biocure Technology Inc. Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest. Each Unit will entitle the holder to receive one common share of the Company (each a "Common Share") and one Full Warrant ("Warrants") exercisable for...
2019-02-14 9:00 AM EST
Biocure Shares DTC Eligible
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that its OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies....
2019-02-07 9:00 AM EST
Biocure Signs a Collaboration Agreement with Y Biologics
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a collaboration agreement with Y Biologics ("YB"), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease. The purpose of this agreement is to research the effectiveness...
2019-01-14 9:00 AM EST
Biocure Operations Report
2018 In BriefPositive Pre-Clinical Trial Results on Leukemia CAR-T Cell Therapy DevelopmentSuccessful Toxicity Tests on Multiple Sclerosis TreatmentAcquired 6,060 Square Meters Land for Biosimilar Manufacturing FacilitiesCompleted OTC ListingSigned Strategic Agreements with Research PartnersExpanded the Board of DirectorsEstablished
2018-11-19 9:15 AM EST
Biocure Announces: Breakthrough Pre-Clinical Trial Results for CAR-T Cells Treatment of Acute Leukemia
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2018) - Biocure Technology Inc. (CSE: CURE) (O
2018-10-16 10:22 AM EDT